Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) traded up 24.1% during mid-day trading on Tuesday . The stock traded as high as C$1.72 and last traded at C$1.70. 892,106 shares changed hands during trading, an increase of 556% from the average session volume of 135,968 shares. The stock had previously closed at C$1.37.
Analyst Upgrades and Downgrades
Separately, Jones Trading lowered shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.
Read Our Latest Analysis on Oncolytics Biotech
Oncolytics Biotech Price Performance
The company has a market capitalization of C$121.78 million, a P/E ratio of -4.40 and a beta of 1.35. The firm's 50-day moving average is C$0.81 and its 200-day moving average is C$0.94. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
